You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review

Article info

Article menu

Download PDFPDF

XML
Dermatology
Protocol
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review

Authors

  • Francisco Gómez-García Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Pedro Jesús Gómez-Arias Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Jorge Hernandez Department of Pharmacy, Hospital Universitario Reina Sofia, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Ana María Montilla Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain University of Cordoba, School of Medicine, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Jesús Gay-Mimbrera Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Macarena Aguilar-Luque Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Isabel Viguera-Guerra Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain Agencia de Evaluación de Tecnologías Sanitarias (AETSA), Consejería de Salud, Junta de Andalucía, Sevilla, Spain PubMed articlesGoogle scholar articles
  • Antonio Velez García-Nieto Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Beatriz Isla-Tejera Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain Department of Pharmacy, Hospital Universitario Reina Sofia, Cordoba, Spain PubMed articlesGoogle scholar articles
  • Juan Ruano Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Cordoba, Cordoba, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Juan Ruano; juanruanoruiz{at}mac.com
View Full Text

Citation

Gómez-García F, Gómez-Arias PJ, Hernandez J, et al
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
BMJ Open 2019;9:e028303. doi: 10.1136/bmjopen-2018-028303

Publication history

  • Received December 3, 2018
  • Revised April 12, 2019
  • Accepted April 15, 2019
  • First published May 22, 2019.
Online issue publication 
February 20, 2022
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.